Overview Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis Status: Completed Trial end date: 2020-09-25 Target enrollment: Participant gender: Summary This study will assess the safety and efficacy of ARQ-154 foam vs placebo applied once a day for 56 days by subjects with scalp and body psoriasis Phase: Phase 2 Details Lead Sponsor: Arcutis Biotherapeutics, Inc.Arcutis, Inc.